More recently (2010), its use was also approved for patients with HER2-over-expressing Metastatic Gastric or Gastroesophageal (GE) Junction Adenocarcinoma (http://www.cancer.gov/cancertopics/druginfo/fda-trastuzumab). This evidence concerns the gene ERBB2 and adenocarcinoma.